SoftOx Solutions A/S

OSL • Healthcare • Biotechnology • Quote as of 10/23/2026 16:25

Company Profile

IndustryBiotechnology

SectorHealthcare

ExchangeOSL

Market Capitalization317.07 mln

Float1,840 mln

Earnings Date11/25/2026

Piotroski F-Score

3 / 9

Below average

Relative Strength

24 / 100

Significantly lagging

Debt / Equity

0.31

Low leverage

ROE

-25.10

Deeply negative

ROA

-21.03

Deeply negative

Business Description

SoftOx Solutions AS is a Norwegian pharmaceutical company focused on developing new products to prevent and treat infections. Its lead product, SoftOx Inhalation Solution, is currently in Phase II clinical trials for treating ventilator-associated pneumonia and other airway infections. The company is also working on a broader range of antimicrobial treatments designed to fight bacteria, viruses, and fungi. Founded in 2012, SoftOx is based in Fornebu, Norway.

Key Fundamentals

EPS-0.01

ROE-25.10

RPS0.00

ROIC-23.46

ROA-21.03

EBITDA, mln-14.46

EV / EBITDA-21.87

EV / EBIT-17.81

Revenue, mln13.88

EV / Revenue20.80

Quote Details

Last 0.1108

Change -0.003 (-2.64%)

Open 0.1106

Volume 9,573,851

Turnover 1,060,783

Average Volume 31,660,668

Financial Ratios

Current Ratio2.25

Price / Book11.78

Debt / Equity0.31

Financial Strength

Piotroski F-Score 3 / 9

Price Performance & Relative Strength

Period	Price Performance	Relative Strength
1 Week	-1.95%	45 / 100
1 Month	-6.42%	30 / 100
2 Months	27.36%	89 / 100
6 Months	12.49%	76 / 100
1 Year	47.73%	76 / 100